--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-23-071602" form_type: "8-K" ticker: "TLSI" cik: "0001826667" company_name: "TriSalus Life Sciences, Inc." filed_at: "2023-06-15T23:59:59+00:00" generated_at: "2026-06-14T00:32:20.421132+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.6 calibrated_materiality_score: 0.6 confidence: "high" source: SEC EDGAR --- # MedTech Acquisition (MTAC) extends deadline to Sept 22; 808,628 shares redeemed ## Summary - Stockholders approved extension of business combination deadline from June 22 to Sept 22, 2023, plus related charter amendments. - 808,628 public shares redeemed at ~$10.49/share; ~$8.48M removed from trust, leaving ~$12M. - Sponsor issued promissory note for up to $137,375.28 (0% interest) to fund monthly extension deposits into trust. - Post-redemption: 1,144,794 public shares outstanding; $45,791.76/month deposit split 50/50 between note and TriSalus. - Charter amendments allow founder share conversion at any time pre-closing and eliminate $5M net tangible asset redemption limit. ## SEC filing metadata - accession: 0001104659-23-071602 - form_type: 8-K - ticker: TLSI - cik: 0001826667 - company_name: TriSalus Life Sciences, Inc. - filed_at: 2023-06-15T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.6 - calibrated_materiality_score: 0.6 - confidence: high - sec_items: 1.01, 2.03, 5.03, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/tm2318652d1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-23-071602 - JSON: https://secwatch.observer/filing/0001104659-23-071602.json - Plain text: https://secwatch.observer/filing/0001104659-23-071602.txt ## Key facts - Debt Financings TriSalus Life Sciences, Inc. incurred loan of up to $137,375.28 with MedTech Acquisition Sponsor LLC at no interest maturing upon the consummation of an initial business combination. - Instrument: loan - Principal: up to $137,375.28 - Counterparty: MedTech Acquisition Sponsor LLC - Rate: no interest - Maturity: upon the consummation of an initial business combination - Event: incurrence source text: ote”) in the aggregate principal amount of up to $137,375.28 to the Company’s sponsor, MedTech Acquisition Sponsor LLC (the “Sponsor”) pursuant to which the Sponsor agreed to loan to the Company up to $137,375.28 to deposit into the Company’s evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm - Governance Changes TriSalus Life Sciences, Inc.: Amended charter to extend business combination deadline to Sept 22, 2023, change authorized share increase vote standard, add Class B-to-Class A conversion right, and remove redemption limitation on net tangible assets (effective 2023-06-12). - Change: charter amendment - Effective: 2023-06-12 source text: On June 12, 2023, the Company held a special meeting of stockholders (the “Meeting”). At the Meeting, the Company’s stockholders approved (1) an amendment to the Company’s Amended and Restated Certificate of Incorporation, including the amendment thereto (the “Charter”), to extend the date by which the Company must consummate its Business Combination from June 22, 2023 to September 22, 2023 (or such earlier date as determined by the Board); (2) an amendment to the Charter such that subject to the rights of the holders of any outstanding class of preferred stock, the number of authorized shares of any class of common stock or preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the outstanding shares of the Company’s capital stock entitled to vote thereon, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law; (3) an amendment to the Charte evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm - Shareholder Votes TriSalus Life Sciences, Inc. shareholders approved Founder Share Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to provide for the right of the holder of the Founder Shares to convert into Class A common stock, par value $0.0001 per share, on a one-for-one basis at any time prior to the closi. - Proposal: charter amendment - Outcome: passed source text: Founder Share Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to provide for the right of the holder of the Founder Shares to convert into Class A common stock, par value $0.0001 per share, on a one-for-one basis at any time prior to the closing of a Business Combination at the option of the holder of the Founder Shares. The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN 7,496,750 572 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm - Shareholder Votes TriSalus Life Sciences, Inc. shareholders approved Extension Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate a Business Combination from June 22, 2023 to September 22, 2023 (or such earlier date as determined by the Board). at the 2023-06-22 meeting. - Proposal: charter amendment - Outcome: passed - Meeting: 2023-06-22 source text: The Extension Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate a Business Combination from June 22, 2023 to September 22, 2023 (or such earlier date as determined by the Board). The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN 6,333,932 1,163,390 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm - Shareholder Votes TriSalus Life Sciences, Inc. shareholders approved Redemption Limitation Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to eliminate the limitation that the Company may not redeem public shares to the extent that such redemption would result in the Company having net tangible assets of less t. - Proposal: charter amendment - Outcome: passed source text: Redemption Limitation Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation to eliminate the limitation that the Company may not redeem public shares to the extent that such redemption would result in the Company having net tangible assets of less than $5,000,001 in order to allow the Company to redeem public shares irrespective of whether such redemption would exceed the redemption limitation. The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN 7,496,690 322 310 evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm - Shareholder Votes TriSalus Life Sciences, Inc. shareholders approved Section 242(b)(2) Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation such that subject to the rights of the holders of any outstanding class of preferred stock, the number of authorized shares of any class of common stock or preferred stock may b. - Proposal: charter amendment - Outcome: passed source text: Section 242(b)(2) Amendment Proposal – a proposal to amend the Company’s amended and restated certificate of incorporation such that subject to the rights of the holders of any outstanding class of preferred stock, the number of authorized shares of any class of common stock or preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the outstanding shares of the Company’s capital stock entitled to vote thereon, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law. The following is a tabulation of the votes with respect to this proposal, which was approved by the Company’s stockholders: FOR AGAINST ABSTAIN common stock 7,496,754 568 0 Class A common stock 1,246,754 568 0 Class B common stock 6,250,000 0 0 evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923071602/0001104659-23-071602-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.